Fig. 2From: Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?Therapeutic scenario for patients with advanced squamous ‘undruggable’ NSCLC (PD-L1 < 50%)Back to article page